spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:   OAB  

 HSMN NewsFeed - 8 Mar 2023
BlueWind Medical Announces Key Milestone as AMA Issues Unique Category III CPT Code for Subfascial Placement of Tibial Neurostimulators
Devices Urology Reimbursement
 HSMN NewsFeed - 9 May 2022
BlueWind Medical Raises $64 Million to Fund Innovative Technology for Overactive Bladder (OAB) Treatment
Devices Urology Venture Capital
 HSMN NewsFeed - 2 Mar 2022
Valencia Technologies Announces FDA Approval of eCoin(R) Therapy to Treat Urinary Urge Incontinence
Devices Urology FDA
 HSMN NewsFeed - 6 Jan 2022
BlueWind Medical(TM) Ltd. Makes Key Additions to Leadership Team
Devices Urology Personnel
 HSMN NewsFeed - 18 Feb 2021
Medtronic Receives FDA Approval for Expanded MRI Labeling of InterStim(TM) SureScan(TM) MRI Leads
Devices Neurology FDA
 HSMN NewsFeed - 6 Oct 2020
Medtronic Announces First Patient Implanted in ELITE Study of InterStim(TM) Micro
Devices Urology
 HSMN NewsFeed - 19 Feb 2019
Bioness StimRouter(R) Neuromodulation System Receives European CE Mark Approval for the Treatment of Overactive Bladder (OAB)
Devices Neurology Urology Regulatory
 HSMN NewsFeed - 24 Sep 2018
Kyorin Receives Approval from Japan's Ministry of Health, Labour and Welfare for Vibegron for Overactive Bladder
Biopharmaceuticals Urology Regulatory
 HSMN NewsFeed - 30 Aug 2018
BlueWind Medical Announces Positive Long-Term Results of the BLUEWIND-RENOVA(TM) Implantable Tibial Nerve Neuromodulator
Devices Urology
 HSMN NewsFeed - 28 Aug 2018
Urovant Sciences Licenses Novel Gene Therapy for Overactive Bladder
Biopharmaceuticals Urology Licensing
 HSMN NewsFeed - 30 Jul 2018
BlueWind Medical Appoints Dr. Roger R. Dmochowski, MD, MMHC, as Chief Medical Officer
Devices Urology Personnel
 HSMN NewsFeed - 14 Jun 2018
BlueWind Medical Receives FDA Approval for Pivotal Trial Design of RENOVA iStim(TM) Implantable Tibial Nerve Neuromodulator for Overactive Bladder
Devices Urology Neurology FDA
 HSMN NewsFeed - 24 Apr 2018
Urovant Sciences Strengthens Executive Management Team with Senior Hires and Establishes U.S. Headquarters in Irvine, California
Biopharmaceuticals Urology Personnel
 HSMN NewsFeed - 15 Nov 2017
Outpost Medicine Appoints Scott Byrd as Chief Executive Officer and Raises $20 Million in Series A Financing Extension
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 18 Jul 2017
Cogentix Medical Signs Agreement to Launch Endo-Urology Product Line in US; Launch to Further Increase Urology Products Growth Rate During 2018
Devices Urology Licensing
 HSMN NewsFeed - 20 Apr 2017
Ash Keswani Joins Cogentix Medical as SVP of Marketing and Business Development
Devices Urology Personnel
 HSMN NewsFeed - 19 Jul 2016
Vensica Medical Completes $500,000 Finance Round
Devices Drug Delivery Urology Venture Capital
 HSMN NewsFeed - 12 Jul 2016
Darin Hammers Appointed President And CEO Of Cogentix Medical, Inc.
Devices Urology Personnel
 HSMN NewsFeed - 15 Jun 2016
BlueWind Medical Announces CE-Mark for the First in the World Miniature Wireless Neurostimulator to Treat Overactive Bladder
Devices Urology Neurology Regulatory
 HSMN NewsFeed - 15 Jun 2016
Brett Reynolds Rejoins Cogentix Medical As Chief Financial Officer
Devices Personnel
 HSMN NewsFeed - 6 Jun 2016
Axonics Receives CE Mark for its Sacral Neuromodulation System for the Treatment of Urinary and Fecal Dysfunction
Devices Regulatory
 HSMN NewsFeed - 21 Mar 2016
Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women
Biopharmaceuticals Urology Drug Delivery FDA
 HSMN NewsFeed - 21 Dec 2015
Axonics Modulation Technologies Announces $38.5 Million Series B Financing
Devices Neurology Urology Venture Capital
 HSMN NewsFeed - 24 Feb 2015
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Cigna
Devices Urology Reimbursement
 HSMN NewsFeed - 2 Jun 2014
Uroplasty Strengthens Board of Directors with Addition of Kevin H. Roche
Devices Urology Personnel
 HSMN NewsFeed - 17 Apr 2014
Uroplasty Names Daniel P. Merz As Vice President Of Healthcare Affairs
Devices Urology Personnel
 HSMN NewsFeed - 29 Oct 2013
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Humana, Inc.
Devices Urology Reimbursement
 HSMN NewsFeed - 10 May 2013
Uroplasty Announces STEP Study 3-Year Results Demonstrate Sustained Therapeutic Effects Of Percutaneous Tibial Nerve Stimulation
Devices Urology
 HSMN NewsFeed - 25 Jan 2013
FDA Approves OXYTROL(R) FOR WOMEN, the First Over-the-Counter Treatment for Overactive Bladder in Women
Biopharmaceuticals Drug Delivery Urology FDA
 HSMN NewsFeed - 6 Dec 2012
Study Demonstrates Percutaneous Tibial Nerve Stimulation Offers More Cost-Effective OAB Treatment Than Sacral Nerve Stimulation
Devices Urology
 HSMN NewsFeed - 15 Oct 2012
Uroplasty Announces Implanted Tibial Nerve Stimulator Long-Term Study Presentation at International Continence Society
Devices Urology
 HSMN NewsFeed - 18 Jul 2012
Uroplasty Announces Coverage Of Percutaneous Tibial Nerve Stimulation Using Its Urgent(R) PC Neuromodulation System From EmblemHealth
Devices Urology Reimbursement
 HSMN NewsFeed - 2 Jul 2012
Antares Pharma Appoints Jonathan S. Jaffe MD Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Dec 2011
Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder
Biopharmaceuticals Drug Delivery Urology FDA
 HSMN NewsFeed - 4 Aug 2011
Antares Pharma Announces Positive Study Results with VIBEX(TM) MTX in Rheumatoid Arthritis Patients
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 11 Jul 2011
Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol(R))
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Apr 2011
Antares Pharma Announces FDA Acceptance of Anturol(R) NDA for Filing
Biopharmaceuticals Urology
 HSMN NewsFeed - 5 Apr 2011
Uroplasty Announces Expanded Insurance Coverage of Posterior Tibial Nerve Stimulation (PTNS) Delivered Using the Urgent(R) PC Neuromodulation System
Devices Urology Reimbursement
 HSMN NewsFeed - 2 Mar 2010
Antares Pharma Announces Completion of Patient Enrollment in Phase 3 Pivotal Trial of Anturol for the Treatment of Overactive Bladder
Biopharmaceuticals Urology Drug Delivery
 HSMN NewsFeed - 20 Jan 2010
Antares Pharma Expands Executive Team and Appoints Pavan Handa as Senior Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2009
OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months
Devices Urology
 HSMN NewsFeed - 25 Sep 2009
Quintiles and Allergan Announce Co-Promotion for Sanctura XR(R)
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 Sep 2009
REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 21 May 2009
Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
Biopharmaceuticals Urology
 HSMN NewsFeed - 24 Apr 2009
New National Survey Shows That Overactive Bladder Symptoms Are Pervasive and Difficult to Manage
Devices Urology
 HSMN NewsFeed - 27 Jan 2009
Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
Biopharmaceuticals Drug Delivery Urology FDA
 HSMN NewsFeed - 31 Oct 2008
Pfizer's TOVIAZ(TM) (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 13 Oct 2008
Antares Pharma Appoints Paul K. Wotton, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Aug 2008
New Treatment Launched to Help Improve Symptoms in People Suffering From Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 22 May 2008
Indevus Pharmaceuticals Licenses Canadian Rights for SANCTURA XR(TM) to Allergan, Inc.
Biopharmaceuticals Licensing Urology
 HSMN NewsFeed - 21 May 2008
Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
Devices Urology
 HSMN NewsFeed - 3 Apr 2008
Uroplasty Plans to Double Sales Force During Fiscal 2009
Devices Urology
 HSMN NewsFeed - 17 Jan 2008
Uroplasty Expands Marketing Program for Urology Practices
Devices Urology
 HSMN NewsFeed - 16 Jan 2008
Recordati Licenses Kentera(R) From Watson Pharmaceuticals Inc. (U.S.A.) for Europe
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Jan 2008
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 3 Jan 2008
Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
Regenerative Medicine Urology
 HSMN NewsFeed - 12 Dec 2007
Uroplasty More Than Doubles its Active Customers in the U.S. Since March
Devices Urology
 HSMN NewsFeed - 26 Nov 2007
Beijing Med-Pharm Announces Exclusive Agreement to Market Enablex(R) in China
Biopharmaceuticals Distribution
 HSMN NewsFeed - 30 Oct 2007
New Therapies Emerging to Challenge Pain Management for Transdermal Patch Growth
Drug Delivery Biopharmaceuticals
 HSMN NewsFeed - 17 Oct 2007
Allergan Announces Completion of Esprit Pharma Acquisition
Biopharmaceuticals Urology Mergers & Acquisitions
 HSMN NewsFeed - 19 Sep 2007
Allergan, Inc. Announces Agreement to Acquire Esprit Pharma, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Aug 2007
Antares Announces Initiation of Pivotal Trial of ANTUROL(TM) for the Treatment of Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 13 Aug 2007
Esprit Pharma Secures Marketing Rights to SANCTURA(R) XR Creating a New Benchmark for Tolerability in the Treatment of Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 6 Aug 2007
Indevus Announces FDA Approval of SANCTURA(R) XR
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 25 Jul 2007
Antares Reaches Agreement with FDA on Special Protocol Assessment for Pivotal Trial of Anturol(TM)
Biopharmaceuticals Urology
 HSMN NewsFeed - 19 Apr 2007
Antares Pharma Announces Positive Results from Application Site Study for ANTUROL(R)
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 1 Feb 2007
Verathon Inc., Maker of BladderScan(R), Issues $10,000 Challenge to Clinicians: Develop Protocol to Study the Relationship Between Bladder Wall Mass and OAB/BPH in Men
Devices Urology
 HSMN NewsFeed - 12 Oct 2006
Indevus Announces Submission of New Drug Application Seeking Approval for SANCTURA XR to Treat Overactive Bladder
Biopharmaceuticals Drug Delivery Urology FDA
 HSMN NewsFeed - 11 Jul 2006
Uroplasty Initiates Clinical Study Comparing Urgent(R) PC to Drug Therapy for Overactive Bladder Treatment
Devices Urology
 HSMN NewsFeed - 7 Jul 2006
Indevus Announces Positive Data from Second Phase III Trial for SANCTURA XR(TM) in Overactive Bladder
Biopharmaceuticals
 HSMN NewsFeed - 26 Jun 2006
Antares Reports On End of Phase II Meeting with FDA for Anturol(TM)
Biopharmaceuticals Urology
 HSMN NewsFeed - 10 May 2006
Uroplasty, Inc. Announces Aetna's National Coverage Policy for Use of the Urgent(R) PC Neurostimulation Device
Devices Urology Reimbursement
Return to NewsFeed  

 Additional items found! 27

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 27 additional stories matching:
OAB
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!